Pacific Center for Financial Services raised its stake in shares of Allergan PLC. (NYSE:AGN) by 805.1% during the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 534 shares of the company’s stock after buying an additional 475 shares during the period. Pacific Center for Financial Services’ holdings in Allergan PLC. were worth $128,000 as of its most recent filing with the SEC.

Several other hedge funds have also modified their holdings of the stock. Oliver Luxxe Assets LLC purchased a new position in Allergan PLC. during the first quarter worth approximately $2,939,000. Berkshire Asset Management LLC PA raised its position in Allergan PLC. by 3.0% in the first quarter. Berkshire Asset Management LLC PA now owns 1,916 shares of the company’s stock worth $458,000 after buying an additional 56 shares during the period. Graybill Bartz & Assoc Ltd. raised its position in Allergan PLC. by 1.5% in the first quarter. Graybill Bartz & Assoc Ltd. now owns 17,635 shares of the company’s stock worth $4,213,000 after buying an additional 255 shares during the period. Cribstone Capital Management LLC raised its position in Allergan PLC. by 3.6% in the first quarter. Cribstone Capital Management LLC now owns 6,803 shares of the company’s stock worth $1,625,000 after buying an additional 236 shares during the period. Finally, Atria Investments LLC raised its position in Allergan PLC. by 35.1% in the first quarter. Atria Investments LLC now owns 7,310 shares of the company’s stock worth $1,747,000 after buying an additional 1,900 shares during the period. Institutional investors and hedge funds own 84.77% of the company’s stock.

Shares of Allergan PLC. (AGN) traded down 1.14% on Thursday, reaching $235.26. 618,142 shares of the company were exchanged. Allergan PLC. has a 12 month low of $184.50 and a 12 month high of $256.80. The company’s 50-day moving average price is $246.68 and its 200 day moving average price is $238.04. The company has a market cap of $78.86 billion, a price-to-earnings ratio of 7.17 and a beta of 1.16.

Allergan PLC. (NYSE:AGN) last released its quarterly earnings data on Thursday, August 3rd. The company reported $4.02 earnings per share for the quarter, beating the consensus estimate of $3.95 by $0.07. The company had revenue of $4.01 billion during the quarter, compared to analyst estimates of $3.95 billion. Allergan PLC. had a net margin of 79.17% and a return on equity of 7.25%. Allergan PLC.’s revenue for the quarter was up 8.8% compared to the same quarter last year. During the same quarter in the previous year, the business posted $3.35 EPS. On average, equities research analysts expect that Allergan PLC. will post $16.25 EPS for the current year.

The business also recently disclosed a quarterly dividend, which will be paid on Friday, September 15th. Stockholders of record on Friday, August 18th will be paid a $0.70 dividend. The ex-dividend date is Wednesday, August 16th. This represents a $2.80 annualized dividend and a dividend yield of 1.18%. Allergan PLC.’s dividend payout ratio is currently 9.95%.

COPYRIGHT VIOLATION NOTICE: “Pacific Center for Financial Services Acquires 475 Shares of Allergan PLC. (NYSE:AGN)” was originally published by Daily Political and is the sole property of of Daily Political. If you are reading this story on another website, it was illegally stolen and reposted in violation of United States and international copyright law. The correct version of this story can be accessed at https://www.dailypolitical.com/2017/08/10/pacific-center-for-financial-services-acquires-475-shares-of-allergan-plc-nyseagn.html.

A number of research firms have commented on AGN. Mizuho restated a “buy” rating and issued a $267.00 price target on shares of Allergan PLC. in a research report on Wednesday, August 2nd. Royal Bank Of Canada set a $285.00 price target on shares of Allergan PLC. and gave the company a “buy” rating in a research report on Thursday, August 3rd. Wells Fargo & Company boosted their price target on shares of Allergan PLC. to $278.00 and gave the company an “outperform” rating in a research report on Thursday, August 3rd. Deutsche Bank AG restated a “buy” rating and issued a $273.00 price target (up from $265.00) on shares of Allergan PLC. in a research report on Monday, July 17th. Finally, Vetr upgraded shares of Allergan PLC. from a “sell” rating to a “hold” rating and set a $242.88 price target on the stock in a research report on Monday, June 26th. Eight research analysts have rated the stock with a hold rating and fifteen have assigned a buy rating to the company’s stock. The stock has a consensus rating of “Buy” and a consensus price target of $274.49.

In other news, Director Nesli Basgoz sold 1,889 shares of Allergan PLC. stock in a transaction on Thursday, May 18th. The shares were sold at an average price of $220.45, for a total value of $416,430.05. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Insiders own 0.36% of the company’s stock.

About Allergan PLC.

Allergan, Inc is a multi-specialty healthcare company. The Company focuses on developing and commercializing pharmaceuticals, biologics, medical devices and over-the-counter (OTC) products. It discovers, develops and commercializes a range of products for the ophthalmic, neurological, medical aesthetics, medical dermatology, breast aesthetics, urological and other specialty markets.

Want to see what other hedge funds are holding AGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Allergan PLC. (NYSE:AGN).

Institutional Ownership by Quarter for Allergan PLC. (NYSE:AGN)

Receive News & Ratings for Allergan PLC. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergan PLC. and related companies with MarketBeat.com's FREE daily email newsletter.